Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Impaired Hepatic Function on the Pharmacokinetics of LY2216684

NCT01241435 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01241435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01241435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Impaired Hepatic Function on the Pharmacokinetics of LY2216684
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2010
Completion date
April 30, 2011
Enrollment
36 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major